Acute myeloblastic leukemia

Advances in Therapy

Volumn 28, Issue SUPPL. 3, 2011, Pages 10-16

  Molina, Carmen Avellaneda ^a   Rodríguez, Maria José Requena ^b   De Marcos, Nieves Somolinos ^c   Font, Patricia ^d  

^a Hospital Universitario San Agustín   (Spain)

^b HOSPITAL SEVERO OCHOA   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Acute myeloblastic leukemia; Azacitidine; Myelodysplastic syndromes

Indexed keywords

AZACITIDINE; CD45 ANTIGEN; CYTARABINE; IDARUBICIN; MITOXANTRONE; PROTEIN ERG1; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

5Q- SYNDROME; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANAPHYLACTOID PURPURA; ARTICLE; BONE MARROW BIOPSY; CARDIOGENIC SHOCK; CASE REPORT; CHROMOSOME 20Q; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERG1 GENE; ERYTHEMA NODOSUM; FAMILY HISTORY; FEBRILE NEUTROPENIA; FEMALE; GENE DELETION; HEART LEFT VENTRICLE FAILURE; HEPATOMEGALY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INFLAMMATION; INTENSIVE CARE UNIT; LEUKEMIA REMISSION; LUNG MYCOSIS; MALE; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; MUTATOR GENE; PANCYTOPENIA; PROGNOSIS; PULMONARY CANDIDIASIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; SKIN NODULE; SPLENOMEGALY; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; ERYTHEMA NODOSUM; FEMALE; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION;

EID: 79959774253     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-010-0109-3     Document Type: Article

References (19)

1. Vidaza® (azacitidine for injection). Prescribing information. Summit, NJ: Celgene Corporation; August 2008. Available at: http://www.vidaza.com/pdf/ PI-FINAL.pdf. Accessed January 25, 2011.
2. Anexo I: Ficha técnica o resumen de las características del producto [in Spanish]. Available at: http://www.ema.europa.eu/docs/es-ES/ document-library/EPAR---Product-Information/human/000978/WC500050239.pdf. Accessed January 25, 2011.
3. National Institute of Cancer: Clinical Trials search results. Available at: http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid= 8723965. Accessed January 25, 2011.
4. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440. (Pubitemid 34525728)
5. Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441-2452. (Pubitemid 34525729)
6. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903. (Pubitemid 46630737)
7. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7:21-29. (Pubitemid 23184796)
8. Silverman LR, Holland JF, Demakos EP, et al. Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol. 1994;68:A12. Abstract 46.
9. Fenaux P, Mufti G, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-232.
10. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in older adult patients with low bone marrow blast count (20-30%) acute myeloid leukemia. J Clin Oncol. 2009;28:562-569.
11. Thépot S, Itzykson R, Seegers V, et al. Azacytidine (AZA) as first line therapy in AML: results of the French ATU program. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 843.
12. Itzykson R, Thépot S, Recher C, et al. Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU program. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1054.
13. Grövdal M, Khan R, Aggerholm A, et al. Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDSAML) in complete remission (CR) after induction chemotherapy. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 223.
14. Gardin C, Prébet T, Bouabdallah K, et al. A phase II study of post-remission therapy with azacitidine (AZA) in patients with AML post-MDS and highrisk MDS: a GFM group study. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 844.
15. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302-2308. (Pubitemid 47523148)
16. Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma. 2008;49:2141-2147
17. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008;113:1596-1604.
18. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York cancer consortium. J Clin Oncol. 2008;26(suppl.). Abstract 7000.
19. Itzykson R, Thépot S, Quesnel B, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45:255-260.